Study S000198

Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04615871
Acronym: SEMPATICO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: UNKNOWN
Enrollment: 400
Start: 2021-09-10
Primary completion: 2022-03-31
Lead sponsor: Vladimír Džavík
Conditions: Covid19; Myocardial Injury
Interventions: DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Composite of death or mechanical ventilation [28 days after randomization]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.